- Home
- CMRX vs BOLD Comparison
CMRX vs BOLD Comparison
Compare CMRX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- BOLD
- Stock Information
- Founded
- CMRX 2000
- BOLD 2018
- Country
- CMRX United States
- BOLD United States
- Employees
- CMRX N/A
- BOLD N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- CMRX Health Care
- BOLD
- Exchange
- CMRX Nasdaq
- BOLD Nasdaq
- Market Cap
- CMRX 77.1M
- BOLD 81.0M
- IPO Year
- CMRX 2013
- BOLD 2024
- Fundamental
- Price
- CMRX $0.86
- BOLD $3.01
- Analyst Decision
- CMRX Strong Buy
- BOLD Strong Buy
- Analyst Count
- CMRX 1
- BOLD 3
- Target Price
- CMRX $11.00
- BOLD $23.00
- AVG Volume (30 Days)
- CMRX 282.9K
- BOLD 64.0K
- Earning Date
- CMRX 11-07-2024
- BOLD 11-07-2024
- Dividend Yield
- CMRX N/A
- BOLD N/A
- EPS Growth
- CMRX N/A
- BOLD N/A
- EPS
- CMRX N/A
- BOLD N/A
- Revenue
- CMRX $159,000.00
- BOLD N/A
- Revenue This Year
- CMRX $1,772.84
- BOLD N/A
- Revenue Next Year
- CMRX N/A
- BOLD N/A
- P/E Ratio
- CMRX N/A
- BOLD N/A
- Revenue Growth
- CMRX N/A
- BOLD N/A
- 52 Week Low
- CMRX $0.75
- BOLD $2.82
- 52 Week High
- CMRX $1.30
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- CMRX 41.07
- BOLD N/A
- Support Level
- CMRX $0.91
- BOLD N/A
- Resistance Level
- CMRX $1.12
- BOLD N/A
- Average True Range (ATR)
- CMRX 0.09
- BOLD 0.00
- MACD
- CMRX -0.01
- BOLD 0.00
- Stochastic Oscillator
- CMRX 10.31
- BOLD 0.00
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.